Cardioprotective effects of vasopeptidase inhibition vs. angiotensin type 1-receptor blockade in spontaneously hypertensive rats on a high salt diet

Hypertension Research

Volumn 27, Issue 8, 2004, Pages 609-618

  Grönholm, Tina ^a,b   Finckenberg, Piet ^c   Palojoki, Eeva ^a,b   Saraste, Antti ^d   Bäcklund, Tom ^a,b   Eriksson, Anders ^a,b   Laine, Mika ^a,b   Mervaala, Eero ^c   Tikkanen, Ilkka ^a,b  

^a MINERVA FOUNDATION INSTITUTE FOR MEDICAL RESEARCH   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TURKU   (Finland)

Author keywords

Angiotensin type 1 receptor blockade; Apoptosis; Cardiac collagen; Hypertension; Vasopeptidase inhibition

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; HYDROCHLOROTHIAZIDE; LOSARTAN; OMAPATRILAT; SODIUM CHLORIDE; VASOPEPTIDASE INHIBITOR;

ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; GENE EXPRESSION; HEART MUSCLE INJURY; HEART WEIGHT; HISTOPATHOLOGY; IN VITRO STUDY; MALE; MONOTHERAPY; NICK END LABELING; NONHUMAN; PLASMA RENIN ACTIVITY; PLETHYSMOGRAPHY; RAT; RECEPTOR BLOCKING; SALT INTAKE; SCORING SYSTEM; SPONTANEOUSLY HYPERTENSIVE RAT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ALDOSTERONE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; AUTORADIOGRAPHY; BODY WEIGHT; CARDIOTONIC AGENTS; FIBROSIS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMMEDIATE-EARLY PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LOSARTAN; MALE; MYOCARDIUM; ORGAN SIZE; PROTEASE INHIBITORS; PYRIDINES; RATS; RATS, INBRED SHR; RENIN; SODIUM CHLORIDE, DIETARY; THIAZEPINES;

EID: 5044232708     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.27.609     Document Type: Article

References (63)

1. Olivetti G, Melissari M, Balbi T, et al: Myocyte cellular hypertrophy is responsible for ventricular remodelling in the hypertrophied heart of middle aged individuals in the absence of cardiac failure. Cardiovasc Res 1994; 28: 1199-1208.
2. Lopez B, Gonzales A, Varo N, Laviades C, Querejeta R, Diez J: Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001; 38: 1222-1226.
3. Dostal DE: Regulation of cardiac collagen: angiotensin and cross-talk with local growth factors. Hypertension 2001; 37: 841-844.
4. Hefti MA, Harder BA, Eppenberger HM, Schaub MC: Signaling pathways in cardiac myocyte hypertrophy. J Mol Cell Cardiol 1997; 29: 2873-2892.
5. Ruiz-Ortega M, Lorenzo O, Ruperez M, et al: Role of the renin-angiotensin system in vascular diseases. Hypertension 2001; 38: 1382-1389.
6. Higaki J, Aoki M, Morishita R, et al: In vivo evidence of the importance of cardiac angiotensin-converting enzyme in the pathogenesis of cardiac hypertrophy. Arterioscler Thromb Vasc Biol 2000; 20: 428-434.
7. Varo N, Etayo JC, Zalba G, et al: Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 1999; 17: 107-114.
8. Brooks WW, Bing OHL, Robinson KG, Slawsky MT, Chaletsky DM, Conrad CH: Effect of angiotensin-converting enzyme inhibition on myocardial fibrosis and function in hypertrophied and failing myocardium from the spontaneously hypertensive rat. Circulation 1997; 96: 4002-4010.
9. Brilla CG, Janicki JS, Weber KT: Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation 1991; 83: 1771-1779.
10. Baba HA, Iwai T, Bauer M, Irlbeck M, Schmid KW, Zimmer HG: Differential effects of angiotensin II receptor blockade on pressure-induced left ventricular hypertrophy and fibrosis in rats. J Mol Cell Cardiol 1999; 31: 445-455.
11. Varo N, Iraburu MJ, Varela M, Lopez B, Etayo JC, Diez J: Chronic AT1 blockade stimulates extracellular collagen type 1 degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35: 1197-1202.
12. Varagic J, Susic D, Frohlich ED: Coronary hemodynamic and ventricular responses to angiotensin type 1 receptor inhibition in SHR. Hypertension 2001; 37: 1399-1403.
13. Pathak M, Sarkar S, Vellaichamy E, Sen S: Role of myocytes in myocardial collagen production. Hypertension 2001; 37, 833-840.
14. Tsutsumi Y, Matsubara H, Ohkubo N, et al: Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 1998; 83: 1035-1046.
15. Lijnen PJ, Petrov VV, Fagard RH: Induction of cardiac fibrosis by transforming growth factor-beta1. Mol Genet Metab 2000; 71: 418-435.
16. Mezzano SA, Ruiz-Ortega M, Egido J: Angiotensin II and renal fibrosis. Hypertension 2001; 38: 635-638.
17. Finckenberg P, Inkinen K, Ahonen J, et al: Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 2003; 163: 355-366.
18. Gupta S, Clarkson MR, Duggan J, Brady HR: Connective tissue growth factor: potential role in glomerulosclerosis and tubulointerstitial fibrosis. Kidney Int 2000; 58: 1389-1399.
19. Moussad EE, Brigstock DR: Connective tissue growth factor: what's in a name ? Mol Genet Metab 2000; 71: 276-292.
20. Duncan MR, Frazier KS, Abramson S, et al: Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: down-regulation by cAMP. FASEB J 1999; 13: 1774-1786.
21. Chen MM, Lam A, Abraham JA, Schreiner GF, Joly AH: CTGF expression is induced by TGF-beta in cardiac fibroblasts and cardiac myocytes: a potential role in heart fibrosis. J Mol Cell Cardiol 2000; 32: 1805-1819.
22. Ihn H: Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol 2002; 14: 681-685.
23. Oemar BS, Werner A, Garnier J-M, et al: Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 1997; 95: 831-839.
24. Hamet P, Richard L, Dam T-V, et al: Apoptosis in target organs of hypertension. Hypertension 1995; 26: 642-648.
25. Liu Y-H, Yang X-P, Sharov VG, et al: Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-1935.
26. Yamamoto S, Sawada K, Shimomura H, et al: On the nature of cell death during remodeling of the hypertrophied human myocardium. J Mol Cell Cardiol 2000; 32: 161-175.
27. Gonzalez A, Lopez B, Ravassa S, et al: Stimulation of cardiac apoptosis in essential hypertension: potential role of angiotensin II. Hypertension 2002; 39: 75-80.
28. Diez J, Panizo A, Hernandez M, et al: Cardiomyocyte apoptosis and cardiac angiotensin-converting enzyme in spontaneously hypertensive rats. Hypertension 1997; 30: 1029-1034.
29. Fortuno MA, Ravassa S, Etayo JC, Diez J: Overexpression of Bax protein and enhanced apoptosis in the left ventricle of spontaneously hypertensive rats: effects of AT1 blockade with losartan. Hypertension 1998; 32: 280-286.
30. Fortuno MA, Ravassa S, Fortuno A, Zalba G, Diez J: Cardiomyocyte apoptotic cell death in arterial hypertension: mechanisms and potential management. Hypertension 2001; 38: 1406-1412.
31. Burnett JC Jr: Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens 1999; 17: S37-S43.
32. Trippodo NC, Robl JA, Asaad MM, Fox M, Panchal BC, Schaeffer TR: Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998; 11: 363-372.
33. Tikkanen T, Tikkanen I, Rockell MD, et al: Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme in rats with hypertension and diabetes mellitus. Hypertension 1998; 32: 778-785.
34. Burrell LM, Droogh J, Man in't Veld O, Rockell MD, Farina NK, Johnston CI: Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens 2000; 13: 1110-1116.
35. Bäcklund T, Palojoki E, Grönholm T, et al: Dual inhibition of angiotensin converting enzyme and neutral endopeptidase by omapatrilat in rat in vivo. Pharmacol Res 2001; 44: 411-418.
36. Makino N, Sugano M, Otsuka S, Hata T: Molecular mechanism of angiotensin II type I and type II receptors in cardiac hypertrophy of spontaneously hypertensive rats. Hypertension 1997; 30: 796-802.
37. Nunez E, Hosoya K, Susic D, Frohlich ED: Enalapril and losartan reduced cardiac mass and improved coronary hemodynamics in SHR. Hypertension 1997; 29: 519-524.
38. Wienen W, Schierok HJ: Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats. JRAAS 2001; 2: 123-128.
39. Finckenberg P, Lassila M, Inkinen K, et al: Cyclosporine induces myocardial connective tissue growth factor in spontaneously hypertensive rats on high-sodium diet. Transplantation 2001; 71: 951-958.
40. Saraste A, Pulkki K, Kallajoki M, Henriksen K, Parvinen M, Voipio-Pulkki L-M: Apoptosis in human acute myocardial infarction. Circulation 1997; 95: 320-323.
41. Palojoki E, Saraste A, Eriksson A, Pulkki K, Kallajoki M, Voipio-Pulkki L-M: Cardiomyocyte apoptosis and ventricular remodeling after myocardial infarction in rats. Am J Physiol Heart Circ Physiol 2001; 280: H2726-H2731.
42. Fyhrquist F, Soveri P, Putula L, Stenman U: Radioimmunoassay of plasma renin activity. Clin Chem 1976; 22: 250-256.
43. Mervaala EMA, Pere A-K, Lindgren L, et al: Effects of dietary sodium and magnesium on cyclosporine A-induced hypertension and nephrotoxicity in spontaneously hypertensive rats. Hypertension 1997; 29: 822-827.
44. Burrell LM, Farina N, Risvanis J, Woollard D, Casely D, Johnston CI: Inhibition of NEP, the degradative enzyme for natriuretic peptides, in rat kidney after oral SCH 42495. Clin Sci 1997; 93: 43-50.
45. Kohzuki M, Johnston CI, Chai SY, et al: Measurement of angiotensin converting enzyme induction and inhibition using quantitative in vitro autoradiography: tissue selective induction after chronic lisinopril treatment. J Hypertens 1991; 9: 579-587.
46. Mervaala EM, Himberg JJ, Laakso J, Tuomainen P, Karppanen H: Beneficial effects of a potassium- and magnesium-enriched salt alternative. Hypertension 1992; 19: 535-540.
47. Yu HCM, Burrell LM, Black MJ, et al: Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998; 98: 2621-2628.
48. Campese VM, Lasseter KC, Ferrario CM, et al: Omapatrilat versus lisinopril; efficacy and neurohormonal profile in salt-sensitive hypertensive patients. Hypertension 2001; 38: 1342-1348.
49. Weber MA: Vasopeptidase inhibitors. Lancet 2001; 358: 1525-1532.
50. Stewen P, Mervaala E, Karppanen H, et al: Sodium load increases renal angiotensin type 1 receptors and decreases bradykinin type 2 receptors. Hypertens Res 2003; 26: 583-589.
51. Hishikawa K, Nakaki T, Fujii T: Connective tissue growth factor induces apoptosis via caspase 3 in cultured human aortic smooth muscle cells. Eur J Pharmacol 2000; 392: 19-22.
52. Narula J, Haider N, Virmani R, et al: Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996; 335: 1182-1189.
53. Olivetti G, Abbi R, Quaini F, et al: Apoptosis in the failing human heart. N Engl J Med 1997; 336: 1131-1141.
54. Kajstura J, Cigola E, Malhotra A, et al: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J Mol Cell Cardiol 1997; 29: 859-870.
55. Contard F, Glukhova M, Marotte F, et al: Diuretic effects on cardiac hypertrophy in the stroke prone spontaneously hypertensive rat. Cardiovasc Res 1993; 27: 429-434.
56. Su JZ, Chen SC, Wu KG, et al: Effects of perindopril, propranolol, and dihydrochlorothiazide on cardiovascular remodelling in spontaneously hypertensive rats. Pharmacol Sin 1999; 20: 923-928.
57. Frohlich ED: Local hemodynamic changes in hypertension: insights for therapeutic preservation of target organs. Hypertension 2001; 38: 1388-1394.
58. Motz W, Vogt M, Scheler S, Strauer BE: Pharmacotherapeutic effects of antihypertensive agents on myocardium and coronary arteries in hypertension. Eur Heart J 1992; 13: 100-106.
59. Silvestre J-S, Robert V, Heymes C, et al: Myocardial production of aldosterone and corticosterone in the rat. J Biol Chem 1998; 273: 4883-4891.
60. Yamamoto N, Yasue H, Mizuno Y, et al: Aldosterone is produced from ventricles in patients with essential hypertension. Hypertension 2002; 39: 958-962.
61. Ito T, Yoshimura M, Nakamura S, et al: Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 2003; 107: 807-810.
62. Zannad F, Dousset B, Alla F: Treatment of congestive heart failure: interfering the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001; 38: 1227-1232.
63. Grandi AM, Imperiale D, Santillo R, et al: Aldosterone antagonist improves diastolic function in essential hypertension. Hypertension 2002; 40: 647-652.